Both $Merck(MRK)$ and $Pfizer(PFE)$have scheduled to announce their second-quarter earnings results on July 28. I like the healthcare sector for its defensive nature amidstprevailing growth uncertainty and market volatility in the broader market. Headwinds from rising costs and interest rate hikes to tame the surging inflation is likely to put pressure on the profit margins and cash-flow valuations. However, the healthcare sector will be more resilient given its price inelasticity of demand for healthcare, as there is usually no effective substitutes for proven drugs for specific diseases and one is more likely to sacrifice a holiday rather than medication and medical treatment for survival. I prefer pharmaceutical companies like MRK and PFE, as unlike start-ups like $Moderna, Inc.(MRNA)$ and $BioNTech SE(BNTX)$, they are not reliant on only COVID-19 vaccine, and they own long lists of cash cows from proven drugs as well as robust pipelines of new drugs in various stage of clinical trials for future cash flows generation. The cash cows will help to finance the experimental drugs which may take years to complete clinical trial and gain regulatory approval, many of which fail in the course. Hence, I would dollar-cost average into MRK and PFE for exposure to the healthcare sector.

@TigerWire@TigerStars@MillionaireTiger

# 💰 Stocks to watch today?(19 Apr)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment29

  • Top
  • Latest
  • LWayne
    ·2022-07-26
    "defensive"? 🤔 i think more of betting on company hitting the jack pot by discovering super medicine.
    Reply
    Report
    Fold Replies
    • pekss
      Yes, but many medicines will fail along the way before they even get to the market.
      2022-07-26
      Reply
      Report
  • GoodLife99
    ·2022-07-26
    monkey p vaccine??
    Reply
    Report
    Fold Replies
    • GoodLife99Replying topekss
      [OK] thanks for sharing [smile]
      2022-07-26
      Reply
      Report
    • pekss
      Our government does not recommend vaccination for that, as the risks outweigh the benefits of the vaccine.
      2022-07-26
      Reply
      Report
  • breAkdaWn
    ·2022-07-27

    Praising Pfizer? for what? if they were really good, the shARE PRICE  would at least be 200, by now. We all know their results by now, earning in billions. 

    Reply
    Report
  • ps14
    ·2022-07-26
    true,  pharmaceutical companies with diverse drugs will definitely be resilient.
    Reply
    Report
  • SandDust
    ·2022-07-26
    Peak is over
    Reply
    Report
  • Mungerism
    ·2022-07-27
    Thanks for sharing
    Reply
    Report
  • Kimlet
    ·2022-07-27
    hmm..
    Reply
    Report
  • Mummysheep
    ·2022-07-27
    tks
    Reply
    Report
  • kianhua84
    ·2022-07-27
    oo
    Reply
    Report
  • Snuka00
    ·2022-07-27
    [Like]
    Reply
    Report
  • AhBeee
    ·2022-07-26
    [Like]
    Reply
    Report
  • jllwang
    ·2022-07-26
    Ok
    Reply
    Report
  • qazwsxedcrfv
    ·2022-07-26
    [Like]
    Reply
    Report
  • lbean
    ·2022-07-26
    👍
    Reply
    Report
  • jllwang
    ·2022-07-26
    Ok
    Reply
    Report
  • Brocco
    ·2022-07-26
    👌🏻
    Reply
    Report
  • Ah Deck
    ·2022-07-26
    Oh
    Reply
    Report
  • gstrader
    ·2022-07-26
    nice
    Reply
    Report
  • stardice
    ·2022-07-26
    OK
    Reply
    Report
  • ok
    Reply
    Report